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Abstract
Background: The Gpnmb gene encodes a transmembrane protein whose function(s) remain
largely unknown. Here, we assess if a mutant allele of Gpnmb confers susceptibility to glaucoma by
altering immune functions. DBA/2J mice have a mutant Gpnmb gene and they develop a form of
glaucoma preceded by a pigment dispersing iris disease and abnormalities of the
immunosuppressive ocular microenvironment.
Results: We find that the Gpnmb genotype of bone-marrow derived cell lineages significantly
influences the iris disease and the elevation of intraocular pressure. GPNMB localizes to multiple
cell types, including pigment producing cells, bone marrow derived F4/80 positive antigen-
presenting cells (APCs) of the iris and dendritic cells. We show that APCs of DBA/2J mice fail to
induce antigen induced immune deviation (a form of tolerance) when treated with TGFβ2. This
demonstrates that some of the immune abnormalities previously identified in DBA/2J mice result
from intrinsic defects in APCs. However, the tested APC defects are not dependent on a mutant
Gpnmb gene. Finally, we show that the Gpnmb mediated iris disease does not require elevated IL18
or mature B or T lymphocytes.
Conclusion: These results establish a role for Gpnmb in bone marrow derived lineages. They
suggest that affects of Gpnmb on innate immunity influence susceptibility to glaucoma in DBA/2J
mice.
Background
The glaucomas are a common group of potentially blind-
ing diseases that by 2010 will affect approximately 60 mil-
lion people worldwide [1]. The glaucomas share a clinical
phenotype including a progressive degeneration of the
optic nerve [2,3]. This glaucomatous optic neuropathy
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causes a progressive and irreversible loss of vision, and
may lead to complete blindness. Significant known risk
factors for glaucoma include elevated intraocular pressure
(IOP), aging, positive family history, race, abnormal optic
nerve head morphology and decreased central corneal
thickness [4-12]. Of these, the only currently modifiable
risk factor is IOP, which is the target of all existing glau-
coma treatments [13-15]. One means of gaining a better
understanding of glaucoma pathogenesis, and ultimately
the creation of new therapeutic interventions, is to study
the underlying molecular pathways with experimental
systems such as the mouse. With the recent descriptions of
mouse strains and techniques relevant to studying glau-
coma, genetic approaches in mice offer great promise for
testing new and potentially novel hypotheses related to
glaucoma [16-19].
Experiments with DBA/2J (D2) mice have suggested that
immune abnormalities may contribute to some forms of
glaucoma [20,21]. D2 mice develop a form of glaucoma
involving a pigment dispersing iris disease that aberrantly
deposits pigment throughout the anterior chamber,
including the drainage structures of the eye [22-24]. As a
consequence, D2 and several closely related strains
develop elevated IOP and glaucomatous neuropathy [24-
30]. Eyes of D2 mice also exhibit multiple abnormalities
in ocular immune privilege [20], including deficient ante-
rior chamber associated immune deviation (ACAID).
Importantly, the iris pigment dispersion component of
the D2 iris disease and the inability to support ACAID are
simultaneously rescued when their marrow is repopulated
with cells from B6D2F1 mice [20]. While the bone mar-
row origin of immune cells involved in ACAID explains
the restoration of ACAID by B6D2F1 bone marrow cells
(BMC), the simultaneous resolution of the pigment dis-
persing iris disease links this disease to bone marrow
derived cells. The B6D2F1 mice that served as a source of
normal BMC are offspring of a cross between glaucoma
prone D2 and normal C57BL/6J (B6) mice. These B6D2F1
mice are heterozygous for all B6 and D2 specific alleles
across the entirety of the autosomal genome. Therefore,
no specific genes were mechanistically implicated in the
recovery of ACAID or the iris disease. The goal of the cur-
rent experiments is to identify the gene(s) responsible for
mediating this BMC contribution to D2 phenotype.
Genetic experiments have previously shown that muta-
tions in two genes digenically promote glaucoma in D2
mice, Tyrp1 and Gpnmb [22,23]. The Tyrp1 gene encodes a
relatively well characterized melanosomal enzyme that is
required for eumelanogenesis and is localized at the
melanosomal membrane. So far there are no reports of
either expression or influence of this gene on cell types
derived from the bone marrow. Therefore, Tyrp1  is
unlikely to be relevant in the BMC mediated glaucoma
phenotype of D2 mice. Less is known concerning Gpnmb.
The Gpnmb gene is predicted to encode a transmembrane
protein with homology to the melanosomal protein, sil-
ver (pMel17), but the function(s) of GPNMB remain
largely unknown. Interestingly, Gpnmb  is expressed by
some BM derived cell types [31]. Recent studies demon-
strate that GPNMB is expressed by macrophages and func-
tions as a negative regulator of macrophage mediated
inflammatory responses [32]. In another study, it was
reported that GPNMB binds activated T cells. This binding
causes inhibition of TCR-induced T-cell activation for
both primary and secondary immune responses [33].
Thus, Gpnmb  is an attractive candidate that potentially
influences the BMC mediated phenotypes in D2 mice.
Here, we test the hypothesis that the Gpnmb gene contrib-
utes to the bone marrow dependent events in D2 glau-
coma. Using D2 mice that only differ in Gpnmb genotype
[34], we demonstrate that BMC lineages containing wild-
type Gpnmb can rescue both the pigment dispersing iris
disease and IOP elevation of D2 mice. Because GPNMB
protein localizes to BM derived antigen-presenting cells
(APCs) of the iris and to cultured dendritic cells, we
assessed potential phenotypes that may be modulated by
these APCs. First, we find that APCs of D2 mice are abnor-
mal in that they fail to induce ACAID, this effect is not
dependent on Gpnmb. Second, we examined aqueous
humor levels of IL18. Bone marrow derived APCs in the
iris are a potential source of IL18 [35] and IL18 is reported
to become elevated in the aqueous humor of D2 mice as
disease progresses [21]. In contrast to the previous report
[21], we find no evidence for involvement of IL18 in the
D2 disease. Surprisingly, we finally show that effectors of
adaptive immune responses, mature B or T lymphocytes,
are not necessary to mediate the glaucoma inducing iris
disease of D2 mice.
Results
Gpnmb is a candidate for mediating BM derived 
contributions to D2 ocular disease
We have previously shown that the D2 iris disease is
strongly influenced by a BMC lineage [20]. Our consider-
ation of candidates capable of mediating this influence
was based in part on previous genetic experiments dem-
onstrating that the D2 iris disease is initiated by the
digenic interaction of the Tyrp1 and Gpnmb genes [22,23].
To ascertain whether either Tyrp1 or Gpnmb are plausible
candidates for mediating the BMC contributions to D2 iris
disease, semi-quantitative RT-PCR was performed to com-
pare gene expression patterns of these genes in iris and
bone marrow. Since valid candidates would likely be
expressed in cells of the immune system, their expression
levels in lymph nodes and thymus were also tested. Sup-
porting a potential role for Gpnmb  in bone marrow
derived phenotypes, expression of Gpnmb was detected inBMC Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2156/9/30
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all of these tissues. In contrast, the expression of Tyrp1 was
limited to only the iris (Fig. 1).
Having found that Gpnmb was expressed in the appropri-
ate tissues, we next assessed the nature of the GpnmbR150X
mutation. The GpnmbR150X mutation in D2 mice creates a
premature stop codon. As a result of nonsense-mediated
mRNA decay, the mutation is predicted to result in a
severe decrease in Gpnmb transcript levels [36]. To test
this, a quantitative real-time PCR assay for Gpnmb was per-
formed. Expression in irides of young predisease D2 mice
homozygous for the GpnmbR150X mutation was compared
to age and sex matched wild-type controls. With samples
normalized to levels of Rn18s, the GpnmbR150X mutation
resulted in a severe reduction in Gpnmb transcript levels
(~18 fold, data not shown). In agreement with this, no
protein with the expected molecular size was detected by
Western analysis using a GPNMB antibody (Fig. 1B). Sim-
ilar analysis of Tyrp1 levels demonstrated no significant
change in transcript levels. The expression of Gpnmb in
immune tissues and the absence of GPNMB protein in
R150X mutants support the hypothesis that this mutation
disrupts BMC lineage dependent functions of GPNMB
and that it may be responsible for bone marrow mediated
aspects of the D2 disease.
A functional requirement for Gpnmb in bone marrow
To genetically test whether the GPNMB genotype of BM
derived lineages influences the D2 iris disease, we took
advantage of the DBA/2J substrain, D2-Gpnmb+ that has a
wild-type Gpnmb allele but no other known differences to
modern D2 mice [34]. Whereas D2 mice with the
GpnmbR150X mutation develop an iris disease characterized
by significant pigment dispersion, iris atrophy, and ante-
rior chamber enlargement, irides of D2-Gpnmb+  mice
exhibit far milder phenotypes (Fig. 2A–J). Using these
mice as donors and recipients in bone marrow transfers,
we next asked whether the genotype of Gpnmb in BMC lin-
eages was capable of influencing iris phenotypes.
Lethally irradiated D2 mice were reconstituted with D2-
Gpnmb+bone marrow and followed clinically for indica-
tions of iris disease (Fig. 2K–O). In all figures and text, the
genotype of donor bone marrow is written first followed
by an arrow and then the recipient genotype. For example,
WT → R150X where D2-Gpnmb+ (WT) bone marrow was
transferred into D2 mice homozygous for the R150X
mutation. At ages when the D2 iris disease is normally
severe, iris phenotypes in D2 mice reconstituted with D2-
Gpnmb+ bone marrow were significantly rescued toward
the wild-type iris phenotype. They developed less pigment
dispersion, less transillumination, and less change in the
dimensions of the anterior chamber as compared to both
unmanipulated D2 mice (compare Fig 2K–O with 2F–J)
and D2 mice that were reconstituted with standard D2
marrow that had the GpnmbR150X mutation [20,37]. The
converse experiment reconstituting lethally irradiated D2-
Gpnmb+ mice with standard D2 bone marrow (R150X →
WT) was also performed (Fig. 2P–T). Iris phenotypes of
D2-Gpnmb+ mice reconstituted with standard D2 bone
marrow were unaltered and maintained an iris indistin-
guishable from unmanipulated D2-Gpnmb+ mice (com-
pare Fig. 2P–T with 2A–E). In sum, these results indicate
that the GpnmbR150Xmutation results in the bone-marrow
derived portion of the D2 iris disease. However, the influ-
ence of the GpnmbR150X mutation acting via bone marrow
derived lineages is not itself sufficient toinduce the iris dis-
ease in otherwise healthy mice.
Gpnmb is a candidate for mediating BM derived contributions  to D2 glaucoma Figure 1
Gpnmb is a candidate for mediating BM derived con-
tributions to D2 glaucoma. A). As expected for a candi-
date capable of mediating the BM derived contributions to 
the D2 form of glaucoma, Gpnmb is expressed in BM derived 
cells. Agarose gel of designated RT-PCR products amplified 
from iris (I), bone marrow (BM), lymph node (L), or thymus 
(T) of normal C57BL/6J mice. (B) Iris lysates from D2 and 
D2-Gpnmb+ mice were analyzed on Western blot with anti-
GPNMB antibody (B). There is no protein of the expected 
size for GPNMB (arrow) in the D2 lysate. The faint bands of 
lower molecular weight likely represent background cross-
reactivity of the antibody.BMC Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2156/9/30
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IOP elevation in D2 mice can be modulated by Gpnmb 
bone marrow genotype
In unmanipulated D2 mice, the depigmenting iris disease
is typically followed by IOP elevation and enlargement of
the anterior chamber. Because the iris disease of D2 mice
reconstituted with D2-Gpnmb+ bone marrow is amelio-
D2-Gpnmb+ bone marrow suppresses iris depigmentation and anterior chamber enlargement Figure 2
D2-Gpnmb+ bone marrow suppresses iris depigmentation and anterior chamber enlargement. Representative 
eyes of the indicated strains and ages are shown. The three left most columns show broad beam illumination to assay for the 
presence of dispersed pigment within the anterior chamber and iris stromal morphology. The fourth column shows a transillu-
minating view assaying the degree of iris depigmentation, detectable as red areas within the image where reflected light is pass-
ing through the iris. The fifth column show anterior chamber dimensions. Each row represents a different genetic context of 
either unmanipulated mice (rows 1 & 2) or bone marrow chimeras (rows 3 & 4). (A to E) Unmanipulated D2-Gpnmb+ mice 
(WT) exhibit a characteristic iris stromal atrophy phenotype caused by the Tyrp1b mutation that is largely devoid of significant 
pigment dispersion at all examined ages (1–15 mo). Eyes of D2-Gpnmb+ mice do not develop significant transillumination and 
maintain a normal anterior chamber depth with very little space between the iris and cornea. (F to J) Unmanipulated D2 mice 
(homozygous for the GpnmbR150X mutation) develop a severe pigment dispersing iris disease. At 5–6 mos, the initial stages of 
iris disease are apparent by a slight peripupillary thickening and subtle changes to the morphology of the iris stroma (note 
slightly roughened appearance). Subsequently, dispersed pigment becomes aberrantly deposited on a variety of structures 
including the surface of the iris, lens, and cornea. Dispersed pigment is also deposited in the aqueous humor drainage struc-
tures, leading to increased IOP and enlargement of the anterior chamber (space indicated by arrows in J). (K to O) D2-
Gpnmb+marrow transferred to D2.GpnmbR150X recipients (WT → R150X) exhibit a pronounced suppression of the typical D2 
disease progression. Most notably, the extent of iris degeneration is lessened (compare the peripupillary region of M vs H, and 
degree of transillumination defects in N vs I) and the anterior chamber does not become enlarged (compare O vs J). (P to T) 
D2 marrow transferred to D2-Gpnmb+ recipients (R150X → WT) exhibit no alterations in ocular phenotype compared to 
unmanipulated D2-Gpnmb+ mice.BMC Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2156/9/30
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rated, and the anterior chamber does not become
enlarged, it is likely that these mice do not develop IOP
elevation. To directly test this, IOP was measured at mul-
tiple ages for bone marrow chimera cohorts and unma-
nipulated D2 mice of differing Gpnmb genotypes (Fig. 3).
10-mo D2-Gpnmb+ mice had a relatively normal mean
IOP of 16 mmHg, 10-mo unmanipulated D2 mice had an
elevated mean IOP of 20 mmHg, and 10-mo D2 mice
reconstituted with D2 marrow (R150X → R150X – a syn-
geneic control for possible influence of bone marrow
transfer itself) also had an elevated IOP of 20 mmHg.
Importantly, 10-mo D2 mice reconstituted with D2-
Gpnmb+ bone marrow (WT → R150X) had a mean IOP of
16 mmHg, indicating that the influence of Gpnmb in bone
marrow was able to prevent IOP elevation from occurring.
Furthermore, the IOP of D2 mice reconstituted with D2-
Gpnmb+ bone marrow (WT → R150X) remained at these
normal levels to at least 16-mo. These results further sup-
port the conclusion that the GpnmbR150X mutation influ-
ences the glaucoma phenotype of D2 mice via BMC
lineages.
GPNMB localization within F4/80 positive APCs
Relatively little is known concerning the Gpnmb gene, or
it's orthologs in other species [38-40]. Although the ocular
localization of GPNMB protein has not previously been
described, experiments have suggested two ocular cell
types in which GPNMB would likely be found. First,
GPNMB is likely to be present in melanin producing cells
[22,41,42]. Second, GPNMB is likely to be present in BM
derived APCs, including macrophages and a subset of
dendritic cells (DCs) [31,32]. In order to begin identifying
specific cell types in which Gpnmb may function, an anti-
GPNMB antibody was used to localize GPNMB in normal
adult C57BL/6J mouse eyes (Fig. 4). In adult C57BL/6J
mice, we found that GPNMB is robustly detectable within
multiple pigmented cells of the eye, including: melano-
cytes of the iris stroma and pigmented cells of the iris pig-
ment epithelium, the pigmented epithelia of the ciliary
body (Fig. 4 A-D), the choroid and to a lesser extent the
retinal pigment epithelium (Fig. 4E, F). Diffuse low level
labeling was observed throughout the neural retina.
GPNMB was not detected in other ocular tissues such as
the cornea or lens. In each of the pigmented tissues,
GPNMB localization was punctate, likely as a conse-
quence of localization within melanosomes. Though
important for other aspects of Gpnmb function [43], there
is no evidence that any of the pigment producing cells of
the eye are derived from the bone marrow. Thus, we next
examined whether GPNMB is present in ocular APCs.
The iris normally contains a robust population of APCs
[44] and GPNMB has previously been demonstrated to be
present in mouse DCs [31]. To determine if a portion of
GPNMB in the iris is within APCs, the APC marker F4/80
was tested for co-localization with GPNMB protein. In
adult C57BL/6J mice, GPNMB was indeed present within
the cytoplasm of iridial F4/80 positive cells (Fig. 4G). To
assess the localization of GPNMB in DC lineages, bone
marrow progenitors were grown in cell culture, stimulated
to differentiate into DCs, and utilized for immunohisto-
chemistry. In DC cells grown in these conditions, GPNMB
was observed in intracellular granules (Fig. 4H). Because
F4/80 positive APCs and DCs are BM derived cell lineages,
this result indicates that the bone marrow functions of
Gpnmb are likely to be mediated, in part or in whole, by
these cells.
Gpnmb deficient APCs fail to induce immune deviation
We next determined the effect of the Gpnmb mutation on
the ability of APCs to induce immune deviation. The
healthy eye exists in a state of immunologic balance that
provides immune protection by decreasing risk of immu-
nopathogenic injury to ocular tissues [45]. Anterior cham-
ber associated immune deviation (ACAID) is an anti-
inflammatory mechanism that is a form of eye-dependent
tolerance mediated by ocular APCs. The immune devia-
Bone marrow genotype affects glaucomatous IOP elevation Figure 3
Bone marrow genotype affects glaucomatous IOP 
elevation. Plot of IOP vs Gpnmb genotype, with age and 
numbers of mice indicated. D2-Gpnmb+ mice exhibit an aver-
age IOP typical of many non-glaucomatous mouse strains. As 
previously described, D2 mice (homozygous for the 
GpnmbR150X mutation) exhibit an elevated IOP at 10 mo of 
age, as do D2 mice receiving syngeneic bone marrow trans-
fers (R150X → R150X). Chimeric mice in which D2-Gpnmb+ 
bone marrow has been transferred into D2 hosts (WT → 
R150X) continue to maintain non-glaucomatous IOP values, 
whether examined at 10 mo, or beyond. The IOPs of both 
Gpnmb+ mice and chimeric mice with Gpnmb+ bone marrow 
were significantly lower than those of all mice with 
GpnmbR150X mutant marrow (P < 0.002 for all comparisons at 
various ages, t test).BMC Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2156/9/30
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tion is initiated by F4/80+ ocular APCs that capture anti-
gen in the eye and migrate via the blood to the spleen
[46]. At that site, these APCs generate a population of reg-
ulatory T cells capable of inhibiting a Th1-mediated
inflammatory immune responses such as a delayed type
hypersensitivity response (DTH). We have previously
demonstrated that D2 mice lack the ability to support
ACAID as evidenced by their inability to inhibit a DTH
response, but the genes responsible for this finding are
not defined [20].
Non-ocular APCs, such as F4/80+ macrophages derived
from thioglycollate-elicited peritoneal exudate cells
(PECs), can be converted into APCs that induce immune
deviation similar to that induced by ocular APCs by
exposing them to TGFβ2 in culture [47-50]. Thus, TGFβ-
exposed peripheral APCs resemble ocular APCs in their
functional phenotype. To test the Gpnmb dependency of
this APC phenotype, we compared the ability of APCs
with differing Gpnmb genotypes to induce immune devia-
tion as detected by inhibition of DTH. To allow experi-
ments with APCs in genetically identical hosts, all
experiments used B6D2F1 mice as recipients. TGFβ2-
treated APCs from control B6 mice with a wild-type
Gpnmb allele successfully induced immune deviation that
led to inhibition of DTH (Fig. 5A). In contrast, APCs from
both Gpnmb  deficient and sufficient D2 mice failed to
induce immune deviation when treated with TGFβ2 (Fig.
5A). Thus, the inability of D2 APCs to mediate immune
deviation is not dependent on Gpnmb alone. This suggests
that some property of D2 APCS other than the GpnmbR150X
mutation is responsible for their inability to induce
immune deviation.
In parallel with these experiments, we tested the ability of
TGFβ-treated APCs from B6.Tyrp1bGpnmbR150X congenic
mice to induce tolerance. These congenic mice have the
D2-derived Tyrp1bGpnmbR150X mutations on a B6 genetic
background (Methods). Also, we evaluated the expression
of a panel of genes for which coordinate changes in
expression normally contribute to the immune deviation
inducing phenotype of APCs [51-53]. Similar to D2 APCs,
the B6.Tyrp1bGpnmbR150X derived APCs failed to induce
immune deviation when treated with TGFβ2 (Fig. 5A).
Arguing against a causative role for the Tyrp1 mutation,
BALB/c mice have the same Tyrp1b mutation but do not
have deficiencies in ACAID [20]. Together, our results sug-
gest that a gene(s) that resides in one of the D2-derived
chromosomal regions may be important in mediating
APC induced tolerance. (D2-derived chromosomal
regions surround the Tyrp1 and Gpnmb genes in the B6
congenic mice [43]). In agreement with this, the coordi-
nated pattern of changes in gene expression that support
immune deviating properties of APCs exhibited a classic
tolerizing pattern in B6 mice, but not in D2 (Figure 5B),
GPNMB localizes to multiple pigmented tissues of the eye  and ocular APCs Figure 4
GPNMB localizes to multiple pigmented tissues of the eye and ocular 
APCs. Cryosections of whole eyes from wild-type C57BL/6J mice were imaged in 
brightfield or phase illumination. GPNMB protein localization was imaged by fluores-
cent immunohistochemistry and confocal microscopy (red). GPNMB is present in: 
(A, B) multiple pigmented tissues of the eye, (C, D) iris and pigmented epithelia of 
the ciliary body, and (E, F) choroid. (G) Iris of normal C57BL/6J mouse showing 
GPNMB (red) within cells labeled by F4/80 (green). An 8 micron Z-series composite 
demonstrating F4/80 labeling the border of a single cell (dashed white circle) contain-
ing GPNMB. (H) BM derived dendritic cell from D2-Gpnmb+ marrow differentiated in 
cell culture showing punctate expression of GPNMB, (I, J) Negative controls were 
labelled and imaged with identical conditions and exhibited negligible signal. (I) Eyes 
from D2 mice (homozygous for GpnmbR150X) have no signal for GPNMB, an inset on 
right hand corner shows the brightfield image of the same section. (J) BM derived 
dendritic cells from D2 mice have no staining for GPNMB. Scale bars A-F, I = 500 
μm, G, H, J = 10 μm.BMC Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2156/9/30
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D2-Gpnmb+  or B6.Tyrp1bGpnmbR150X  APCs (data not
shown).
Neither Gpnmb genotype, nor age, influence aqueous 
humor levels of IL18
As an additional step toward defining the potential BM
derived functions of Gpnmb, we next tested whether
Gpnmb  genotype influences IL18. Secretion of IL18 by
macrophages has been implicated in both Th1 and Th2
immune responses. Aqueous humor levels of the immune
modulating cytokine IL18 are reported to become ele-
vated in D2 mice, and the levels of IL18 were suggested to
associate with increases in IOP [21]. To test whether
Gpnmb genotype influences IL18 levels, aqueous humor
was collected from cohorts of either D2 or
B6.Tyrp1bGpnmbR150X  mice homozygous for the
GpnmbR150X mutation and compared to the strain matched
controls, D2-Gpnmb+ or C57BL/6J (Fig. 6A). Additionally,
expression of IL18 mRNA in tissue enriched in ciliary
body was analyzed by real-time PCR (Fig. 6B). In these
mice, there was no correlation between Gpnmb genotype
and IL18 levels. Furthermore, in contrast to previous stud-
ies of IL18 in D2 mice [21], we also found no correlation
between IL18 and age. Indeed, in our studies, IL18 levels
were significantly lower in 9 mo old D2 mice compared to
3 and 6 mo old D2 mice (P < 0.05). These results fail to
support a role for IL18 in the D2 form of glaucoma and
suggest that the relevant bone marrow derived functions
of Gpnmb do not influence this aspect of ocular immunity.
Deficiency of Rag1 does not affect Gpnmb mediated 
disease
GPNMB is present within APCs and APCs initiate and
direct adaptive immune responses. Therefore, we tested
whether mature B or T lymphocytes, play a role in the
Gpnmb  mediated iris disease. To accomplish this, we
exploited a mutation in the recombination activating gene
Rag1. Mice deficient for Rag1 are characterized by arrested
development of T and B cells and are therefore incapable
of adaptive immune reactions mediated by mature T or B
cells. To test the necessity of T and B cells for the pigment
dispersing iris disease, we utilized B6.Tyrp1bGpnmbR150X
mice [43] with a Rag1 mutation. As a consequence of the
D2-derived  Tyrp1b  and  GpnmbR150X  mutations,
B6.Tyrp1bGpnmbR150X mice develop an iris disease with
near identical features to that of D2 mice [43]. Ablating
the adaptive immune functions of T and B cell had no
effect on the iris disease of these mice. The iris disease of
Rag1 deficient B6.Tyrp1bGpnmbR150X mice is indistinguish-
able to that of their littermates with a functional Rag1
gene and an intact adaptive immune system (Fig. 7). Sim-
ilar results were obtained with mice homozygous for the
Prkdcscid mutation that also lack mature B and T lym-
phocytes [see Additional File 1]. These experiments dem-
onstrate that the loss of adaptive immune reactions has no
influence on the age of onset, rate of progression, or final
severity of the iris disease mediated by Tyrp1 and Gpnmb
mutations. Given the dependence of disease phenotypes
on the Gpnmb genotype of bone marrow but not on adap-
tive immunity, these results suggest that GPNMB may
impact innate immune processes. Therefore, alterations of
Tolerogenic capacities and expression profiles of Gpnmb defi- cient APCs Figure 5
Tolerogenic capacities and expression profiles of Gpnmb deficient APCs. 
(A) OVA-pulsed APCs isolated from mice of the indicated genotypes were injected 
into B6D2F1/J recipients. Their ability to induce immune deviation was then meas-
ured. Absence of ear swelling indicated functional immune deviation through the sup-
pression of a DTH response to the OVA challenge. We then tested their ability to 
induce immune deviation as detected by inhibition of DTH i.e. suppression of ear 
swelling in response to OVA challenge. The experimental summary for each group 
follows: Untreated (APCs cultured in media, injected into mice, immunization, chal-
lenge), TGFβ2-treated (APCs cultured in presence of TGFβ2, injected into mice, 
immunization, challenge), Neg. Control (challenge only). Induction of immune devia-
tion is detected as the suppression of ear swelling response in the TGFβ2-treated 
groups as compared to the untreated group. Ear swelling responses are presented as 
mean ± SEM. (B-C) Gene expression profiles of APCs from indicated genotypes. 
Real-time PCR was employed to determine the expression levels of the indicated 
genes and expression of each gene was normalized to Gapdh. To faciliate visualization 
of the overall pattern of gene expression changes across these genes, the expression 
changes in response to TGFβ2-treatment are summarized with an arrow (indicating 
up or down regulation) or a dash (indicating no change). TSP, thrombospondin 1, offi-
cial gene name Thbs1; TGFβ2, transforming growth factor, beta 2; TNFR2, tumor 
necrosis factor receptor superfamily, member 1b, official gene name Tnfrsf1b; CD40, 
CD40 antigen; IL-6, interleukin 6.BMC Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2156/9/30
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innate immunity may participate in the pathogenesis of
the iris disease.
Discussion
D2 mice develop a pigmentary form of glaucoma involv-
ing a pigment dispersing iris disease, increased IOP, and
degeneration of retinal ganglion cells [22-24,26]. In
recent years, we have begun to study early events within
the anterior chamber that initiate the iris disease and IOP
elevation [20,22,23,43] as well as later events associated
with the neurodegeneration [37,54,55]. We have previ-
ously identified two genes responsible for the initiation of
this disease, Tyrp1  and  Gpnmb, both of which encode
melanosomal proteins [22,42,56]. We have also shown
that a non-melanosomal component contributes to the
D2 iris disease which acts via a BMC lineage [20]. Here, we
have identified the Gpnmb  gene as an important gene
influencing these bone marrow derived contributions.
IL18 levels do not become elevated in D2 aqueous humor or ciliary body Figure 6
IL18 levels do not become elevated in D2 aqueous humor or ciliary body. (A) IL18 levels in aqueous humor of age matched D2, D2-Gpnmb+, B6.Tyrp1bGpnmbR150X, and 
C57BL/6J mice were determined by ELISA. IL18 levels are expressed as mean +/- SEM from 5 aqueous humor samples in each group. (B) Quantitative RT-PCR analysis compar-
ing expression levels of IL18 transcript in ciliary body enriched dissections of 10.5 mo old D2, D2.Gpnmb+ and B6.Tyrp1bGpnmbR150X mice. The threshold cycle was calculated with 
normalization to Rn18s and values are expressed as mean +/- SEM, with 3–5 samples in each group.
Loss of adaptive immune reactions has no influence on Gpnmb mediated iris disease Figure 7
Loss of adaptive immune reactions has no influence on Gpnmb mediated iris disease. The Rag1tm1Mom mutation acts recessively to result in a loss of adaptive immune 
responses due to lack of mature B and T lymphocytes. Stocks carrying this mutation were bred to B6.Tyrp1bGpnmbR150X mice. Triple mutant mice were isolated and aged, with 
typical eyes of indicated genotypes shown. The analysis strikingly demonstrates that the immune deficiency associated with Rag1 mutation has no effect on Gpnmb mediated iris 
disease. (A) Eyes of young B6 mice with wild-type Tyrp1, Gpnmb, and Rag1 alleles have healthy irides. (B) At 15 mo, mice mutant for Tyrp1 and Gpnmb exhibit iris disease char-
acterized by significant pigment dispersion and iris atrophy. n = 10 eyes, age range 14–16 mo.(C) At 15 mo, immune deficient mice mutant for Tyrp1, Gpnmb, and Rag1 exhibit an 
iris disease indistinguishable from immune competent mice on the same genetic background. N = 26 eyes.BMC Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2156/9/30
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From the sum of prior and present experiments (see Addi-
tional File 2 and refs [20,22]), an attractive hypothesis
suggests that the D2 iris disease initially involves a
melanosomal defect mediated by the Tyrp1 and Gpnmb
genes that mildly damages the iris and causes cellular
debris, including pigment, to be shed into the anterior
chamber. Due to deficiency of GPNMB, a bone marrow
derived lineage(s) that would normally express Gpnmb
then reacts abnormally to the iris debris. This results in an
inflammatory attack on the iris, severe iris atrophy and the
ensuing glaucoma. The abnormally responding bone
marrow derived lineage may either fail to inhibit ocular
inflammation or may actively promote an inflammatory
attack on the iris. This model accounts for the ability of
B6D2F1 [20] or D2-Gpnmb+ (Fig. 2) bone marrow to sup-
press the D2 iris disease (because bone derived cells with
wild-type Gpnmb alleles do not respond abnormally to the
debris resulting from the melanosomal insults and mild
iris damage). Additionally, this model explains why bone
marrow from D2 mice with the GpnmbR150X mutation is
not sufficient to confer the severe iris disease when trans-
planted into recipient mice with wild-type Gpnmb alleles
(because the recipients with wild-type Gpnmb alleles do
not have sufficient iris damage to prime the immune sys-
tem attack of the iris.). Thus, this model, explains why the
bone marrow derived function of Gpnmb is a necessary,
but not sufficient, component of the overall disease.
The functions of Gpnmb in BMC derived lineage(s) that
are relevant to DBA/2J glaucoma remain unknown.
Although Gpnmb genotype did not influence the ability of
D2 APCs to mediate tolerance to OVA when they were
first exposed to TGFβ2 and OVA in culture, GPNMB may
still modulate some aspects of APCs that contribute to D2
phenotype and were not assessed. These functions may
include their ability to process and present antigens
derived from damaged iris cells, their ability to secrete var-
ious chemokines that recruit proinflammatory cells or
their ability to respond to anti-inflammatory molecules in
the ocular microenvironment. Regardless, we show that
the immune abnormalities contributing to the Gpnmb
mediated iris disease do not require functions of the adap-
tive immune system. This suggests that GPNMB deficiency
may influence innate immune cells that are of bone mar-
row origin and are likely to respond to abnormalities in
the iris. Experimental expression of GPNMB in activated
macrophage causes reduced release of proinflammatory
cytokines such as IL6, IL12 and TNF alpha [32]. We local-
ize GPNMB within APCs. Therefore, it is possible that the
GpnmbR150X mutation alters APCs so that they are more
prone to mediate inflammation and this abnormal phe-
notype promotes ocular inflammation in D2 mice.
Other groups have previously localized GPNMB in macro-
phages and in the MHC class II compartment of DCs [31].
The punctate localization of GPNMB in pigmented cells
and its melanosomal targeting sequence are consistent
with another function of GPNMB in melanosomes [22].
Interestingly, melanosomes and the MHC class II com-
partment are both lysosome-related organelles [57,58].
This correlation suggests that similar to molecules such as
BLOC complexes and LYST [59,60], GPNMB may be a
molecule that functions in multiple classes of lysosome-
related organelles.
The glaucomatous potential of the DBA/2J iris disease has
recently been shown to be strikingly sensitive to genetic
background [43]. When transferred to the C57BL/6J
genetic background, the GpnmbR150X and Tyrp1b mutations
result in a severe pigment dispersing iris disease that is
phenotypically indistinguishable from the iris disease of
D2 mice. Surprisingly, however, these B6 mice are resist-
ant to IOP elevation and glaucoma. Thus, there are addi-
tional modifier genes whose alleles determine whether or
not IOP becomes elevated and glaucoma ensues.
Although these modifier genes remain to be identified,
our preliminary data suggest existence of at least 3 genetic
loci, on different chromosomes to Gpnmb and Tyrp1, that
impact the nature of the anterior chamber disease and
determine if IOP becomes elevated. Given the depend-
ence of the iris disease on bone marrow genotype, at least
some of these modifiers are likely to influence immune
functions. Since the chromosomal region containing
either Gpnmb or Tyrp1 transferred the inability of APCs to
mediate tolerance to the B6 congenic strain, there must be
another strain specific allele that influences APC func-
tions. Efforts to identify these strain specific modifier alle-
les are underway and are likely to shed additional light on
the molecular basis of immune contributions to this glau-
coma. Characterizing these genes is expected to improve
understanding of APC responses within the anterior
chamber and mechanisms of inducing tolerance.
Conclusion
We have demonstrated that Gpnmb influences the glau-
coma phenotype of D2 mice by a BM derived mechanism
that does not require adaptive immunity. Although
immunity has not yet been shown to contribute to human
pigmentary glaucoma, the inflammation is subclinical in
the mice and may have been undetectable on standard
examination of patient's eyes. Thus, similar mechanisms
of mild inflammation may be active in human pigmen-
tary glaucoma and perhaps other ocular diseases in which
pigment dispersal occurs within the anterior chamber.
These findings represent an important step toward gain-
ing a molecular understanding of the mechanisms active
in this pigmentary form of glaucomaBMC Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2156/9/30
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Methods
Animal husbandry
D2 mice were obtained from The Jackson Laboratory, Bar
Harbor, Maine. Some studies also utilized B6.D2-
Tyrp1bGpnmbR150X/Sj mice (referred to as B6
Tyrp1bGpnmbR150X), an N10 congenic strain of mice which
are homozygous for chromosomal intervals containing
the D2-derived Tyrp1b  and  GpnmbR150X  mutations that
have been backcrossed into the C57BL/6J genetic back-
ground [43]. Mice with a recombination activating gene 1
mutation (Rag1tm1Mom) were obtained from The Jackson
Laboratory and crossed to the B6.Tyrp1b GpnmbR150X strain
to produce mutants that were homozygous for all three
mutations (B6.Cg-Rag1tm1MomTyrp1bGpnmbR150X/Sj,
referred to as Rag1  mutant B6 Tyrp1bGpnmbR150X). Two
strains of control mice with wild-type Gpnmb alleles were
utilized in these studies, DBA/2J with a wild-type Gpnmb
allele (DBA/2J-Gpnmb+/Sj, referred to as D2-Gpnmb+) [34]
and C57BL/6J. Since the Gpnmb+allele is the ancestral D2
allele, the GpnmbR150X mutation is the only known genetic
difference between the D2 and D2-Gpnmb+ strains [22].
C57BL/6J mice (with wild-type Tyrp1 and Gpnmb alleles)
were obtained from The Jackson Laboratory. All D2 back-
ground mice were maintained on a 6% fat NIH 31 diet
provided ad libitum, and the water was acidified to pH
2.8–3.2. All B6 background mice were similarly main-
tained but on an NIH 31 diet with 4% fat content. Mice
were housed in cages containing white pine bedding and
covered with polyester filters. The environment was kept
at 21°C with a 14-h light:10-h dark cycle. All animals were
treated according to the guidelines of the Association for
Research in Vision and Ophthalmology for use of animals
in research. All experimental protocols were approved by
the Animal Care and Use Committee of The Jackson Lab-
oratory or The University of Iowa.
Generation and analysis of bone marrow chimeras
Bone marrow chimeras were generated as follows: 4–8 wk
old female D2 and D2-Gpnmb+ mice were lethally irradi-
ated (1000 rad from a 137Cs source) and then received 200
μl intravenous injections containing 5 × 106  T cell
depleted bone marrow cells from the indicated donor
strains. Donor marrow was depleted of T lymphocytes
with 10 μg/mL of purified monoclonal antibodies to CD4
(GK1.5; The Jackson Laboratory Flow Cytometry Service,
Bar Harbor, Maine) and CD8a (53–6.72; The Jackson Lab-
oratory Flow Cytometry Service). Eyes of chimeras were
clinically assayed at 2–3 mo intervals.
Intraocular pressure measurement
IOP was measured using the microneedle method as pre-
viously described in detail [61,62]. Because the IOPs of B6
mice are very consistent, B6 mice were interspersed with
experimental mice during all experiments as a methodo-
logical control to ensure proper equipment calibration
and performance.
Slit-lamp examination
Eyes were examined with a slit-lamp bio-microscope and
photographed with a 40× objective lens. Phenotypic
assessment of iris disease was determined by indices of iris
atrophy dispersed pigment and transillumination defects
following previously described criteria [20,22-24]. Tran-
sillumination is an assay of iris disease whereby reflected
light passing through depigmented areas of iris tissue are
visualized as red light.
RNA Isolation and Quantitative RT-PCR
Tissues were dissected, homogenized, and total RNA
extracted. cDNA was generated using 300 ng of total RNA
isolated from dissected irides or 70 ng of total RNA iso-
lated from ciliary body enriched dissections. Real-time
PCR data were collected utilizing standard reaction condi-
tions, with primer efficiencies determined from serial
dilutions of cDNA and relative expression calculated as
previously published [63-65]. Reaction conditions and
primer sequences are available upon request.
Western blotting
Iris tissue from D2 and D2-Gpnmb+ was homogenized in
lysis buffer (10 mM Tris pH 7.6, 150 mM NACl, 1% Triton
X-100 and supplemented with protease inhibitors). The
lysate was resolved on a 4–20% SDS-PAGE gradient gel.
Proteins were blotted to a PVDF membrane, followed by
incubation with anti-GPNMB antibody (R&D systems),
secondary antibody and detected using SuperSignal West
Pico chemiluminescent substrate (Pierce Biotechnology).
Immunohistochemistry
Enucleated eyes were embedded in Optimal Cutting Tem-
perature embedding medium (Tissue-Tek O.C.T. Com-
pound, Sakura Finetek U.S.A., Inc., Torrance, CA), seven-
micrometer sections cut, and sections transferred to glass
slides (CryoJane, Instrumedics, Inc., St. Louis, MO). Cryo-
sections were air dried for 30 min at room temperature,
fixed for 5 min in ice-cold acetone, again air dried for 30
min at room temperature, and rehydrated in PBS for 5
min. Sections were blocked 1 hr at room temperature with
10% normal donkey serum and 30 mg/mL BSA in PBS.
Primary antibodies were applied for 1 hr at room temper-
ature using polyclonal rabbit anti-GPNMB antibody
(diluted 1:200; R&D Systems Inc., Minneapolis, MN) or
anti-F4/80 (diluted 1:200; Serotec Inc., Raleigh, NC). Pri-
mary antibody was removed by three washes (5 min each)
in PBS and the sections were treated for 1 hr at room tem-
perature with AlexaFluor conjugated secondary antibod-
ies (1:200 dilution, Invitrogen-Molecular Probes,
Carlsbad, CA) diluted in 1% normal donkey serum and
10 mg/mL BSA in PBS. After three washes in PBS, the sec-BMC Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2156/9/30
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tions were mounted (Vectashield, Vector Laboratories,
Burlingame, CA) and viewed by fluorescence microscopy.
All photomicrographs were taken with identical camera
settings. For studies of bone marrow derived dendritic cell
cultures, cells were fixed in 4% paraformaldehyde for 20
min at room temperature. Cells were permeabilized with
PBS containing 0.1% Triton X-100, incubated with poly-
clonal rabbit anti-GPNMB antibody (diluted 1:200; R&D
Systems Inc., Minneapolis, MN) for 1 hr at room temper-
ature, washed three times in PBS, and treated for 1 hr at
room temperature with FITC conjugated secondary anti-
bodies (1:200 dilution, Jackson Immunoresearch, West
Grove, PA). After three washes in PBS, the cells were
mounted in fluorescent mounting medium (Vectashield,
Vector Laboratories, Burlingame, CA) and viewed by con-
focal microscopy.
Bone marrow derived dendritic cell cultures
BM derived cells obtained from D2 or D2-Gpnmb+ mouse
femur were cultured in the presence of GM-CSF (20 ng/
ml) in 24 well plates (Costar Corp., Cambridge, MA). The
nonadherent cells were removed from the culture and
replated with fresh medium containing GM-CSF every
alternate day. On day 10, cells were harvested and a subset
analysed by flow cytometry. In the current experiments,
>95% of cells labeled positive for the mouse APC marker
CD11c.
Analysis of aqueous humor IL18
Aqueous humor was collected as described previously
[21]. IL18 protein level in the aqueous humor was meas-
ured using a commercially available ELISA assay follow-
ing the manufacturer's recommended protocol (Bender
MedSystems, San Bruno, CA). Since overall protein levels
in D2 aqueous humor are increased in older mice (at 6
and 9 mo) [20], samples were compared by analyzing
equal volumes of aqueous humor rather than normaliz-
ing to total protein.
Assay for immune deviation
Peritoneal exudate cells (PECs) were obtained 3 days fol-
lowing 2 ml intra-peritoneal injections of a 3% thioglycol-
late solution (Sigma-Aldrich, St. Louis, MO). Plastic
adherent macrophages from these cells were used as APCs
(>95% F4/80+). Cells were cultured overnight (1 × 105/
well) in a 96-well plate in the presence of TGFβ2 (R&D
Systems, CA, USA, 5 ng/ml final concentration) in serum
free culture media, and pulsed with ovalbumin antigen
(OVA) (7 mg/ml). Adherent cells were harvested, after
washing off culture medium with cold Hank's balanced
salt solution, and intravenously injected into B6D2F1
recipients (5 × 10 3 cells/mouse). Seven days following,
recipients were immunized subcutaneously into the nape
of the neck with OVA/CFA (50 μg). Animals that did not
receive any APCs or immunization served as a negative
control. A week later, animals in all groups received intra-
dermal inoculation of OVA (200 μg/20 μl) into their right
ear pinna. The left ear served as an untreated control.
Thickness of both ears was measured immediately before
and at 24-h interval after the OVA injection using a
micrometer (Mitutoyo 227-101, MTI Corp., Paramus, NJ,
USA). The measurements were performed in triplicates.
Delayed type hypersensitivity (DTH) was measured as ear
swelling [(24-h measurement – 0-h measurement in the
experimental ear) – (24-h measurement – 0-h measure-
ment in the untreated control ear)]. Immune deviation
was detected as the suppression in DTH in the recipients
of TGFβ2 treated APCs as compared to those infused with
untreated APCs. A two-tailed Student's t-test was used
with significance assumed at P < 0.05. DTH results were
confirmed by repeating the experiments a second time.
Serum free medium
Serum-free medium (SFM) was used for in vitro assays.
The medium contained: RPMI-1640, 10 mM HEPES, 0.1
mM NEAA, 1 mM Sodium pyruvate, 100 U/ml Penicillin,
100 mg/ml Streptomycin (Bio Whittaker, Walksville,
MD), 0.1% BSA (Sigma-Aldrich, St. Louis, MO) and ITS+
culture supplement [1 μg/ml iron-free transferrin, 10 ng/
ml linoleic acid, 0.3 ng/ml Na2Se and 0.2 μg/ml
Fe(NO3)3] (Collaborative Biomedical Products, Bedford,
MA).
Genetic nomenclature and stocks
The official full names of genes (with abbreviations in
parentheses), alleles, and stocks utilized in this study are
as follows. 1. Glycoprotein (transmembrane) nmb
(Gpnmb). The ipd allele of Gpnmb results from the R150X
premature stop codon mutation, GpnmbR150X  [22]. 2.
Tyrosinase-related protein 1 (Tyrp1). The b allele of Tyrp1
encodes two amino acid substitutions compared to the
C57BL/6J-derived allele [56]. This D2 allele is also
referred to as isa in the mouse genome database and else-
where [22,23]. The DBA/2J stock utilized here was stock
number 000671 from The Jackson Laboratory. 3. Recom-
bination activating gene 1 (Rag1). The tm1Mom mutation
is a targeted knock-out [66]. The Rag1tm1Mom stock utilized
here was B6.129S7-Rag1tm1Mom/J (stock 002216 from The
Jackson Laboratory). 4. Protein kinase, DNA activated,
catalytic polypeptide (Prkdc). The scid  mutation arose
spontaneously in the CB17 strain and has since been
backcrossed onto C57BL/6J genetic background [67]. The
Prkdcscid  stock utilized here was B6.CB17-Prkdcscid/SzJ
(stock 001913 from The Jackson Laboratory).
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